Clinical Trials Logo

Filter by:
NCT ID: NCT03968523 Completed - Postoperative Pain Clinical Trials

Loco/Regional Anaesthesia Evaluation in Laparoscopic Hernioplasty

Start date: April 23, 2019
Phase: N/A
Study type: Interventional

Laparoscopic hernioplasty is associated with lesser postoperative pain and quick return to work. TAP block is the gold standard technique in this type of hernioplasty. Our aim is to compare TAP block with a novel local infiltration technique that uses direct laparoscopical vision.

NCT ID: NCT03968393 Recruiting - Stroke Clinical Trials

Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative AF After Noncardiac Surgery

ASPIRE-AF
Start date: June 14, 2019
Phase: Phase 4
Study type: Interventional

Multinational, investigator-initiated study of oral anticoagulation versus no anticoagulation for the prevention of stroke and other adverse cardiovascular events in patients with transient perioperative atrial fibrillation after noncardiac surgery and additional stroke risk factors.

NCT ID: NCT03964415 Completed - Healthy Clinical Trials

A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals

MOSAICO
Start date: October 31, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the vaccine efficacy (VE) of a heterologous vaccine regimen utilizing Ad26.Mos4.HIV and aluminum phosphate-adjuvanted Clade C gp140 and Mosaic gp140 for the prevention of HIV-1 infection in HIV-1 seronegative cis-gender men and transgender individuals having sex with cis-gender men and/or transgender individuals.

NCT ID: NCT03963622 Recruiting - ARDS Clinical Trials

Careful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19)

CAVIARDS
Start date: November 23, 2020
Phase: N/A
Study type: Interventional

This is a multicenter randomized controlled clinical trial with an adaptive design assessing the efficacy of setting the ventilator based on measurements of respiratory mechanics (recruitability and effort) to reduce Day 60 mortality in patients with acute respiratory distress syndrome (ARDS). The CAVIARDS study is also a basket trial; a basket trial design examines a single intervention in multiple disease populations. CAVIARDS consists of an identical 2-arm mechanical ventilation protocol implemented in two different study populations (COVID-19 and non-COVID-19 patients). As per a typical basket trial design, the operational structure of both the COVID-19 substudy (CAVIARDS-19) and non-COVID-19 substudy (CAVIARDS-all) is shared (recruitment, procedures, data collection, analysis, management, etc.).

NCT ID: NCT03958877 Recruiting - Clinical trials for Multiple Sclerosis, Relapsing-Remitting

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Start date: October 18, 2019
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple sclerosis (RRMS) and to assess the pharmacokinetics (PK) of BIIB017 in pediatric participants with RRMS in Part 1. In Part 2, the study will evaluate the long-term safety of BIIB017 and further describe safety and the long-term multiple sclerosis (MS) outcomes after BIIB017 treatment in participants who completed the study treatment at Week 96 in Part 1 of the study.

NCT ID: NCT03957031 Completed - Cancer, Gastric Clinical Trials

Gastric Cancer Risk Factors Associated With EU and CELAC Populations

LEGACY-1
Start date: May 31, 2019
Phase:
Study type: Observational

The study uses a case-control design that examines the differences in types of exposures between cases defined with a pathological confirmation of GC diagnosis, and controls, defined as patients to whom a gastroscopy was indicated and confirmed absent of GC i

NCT ID: NCT03955913 Completed - Urothelial Cancer Clinical Trials

A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations

Start date: August 1, 2019
Phase:
Study type: Observational

The purpose of this non-interventional study is to identify participants with urothelial cancer (UC) and selected fibroblast growth factor receptor (FGFR) aberrations through molecular testing of their archival tumor tissue.

NCT ID: NCT03955900 Completed - Multiple Myeloma Clinical Trials

A Registry Study of Participants With Multiple Myeloma in Latin America

MYLACRE
Start date: May 29, 2019
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to characterize the multiple myeloma (MM) population concerning demographics and clinical characteristics (for example. frailty, risk strata, manifestations of target organ damage [TOD]) in 6 countries (that is Argentina, Brazil, Mexico, Chile, Colombia and Panama); and to profile the treatment landscape of Latin American MM participants, including factors associated with health-care provider (HCP) selections of different treatment regimens. These factors can include a participant's demographic and clinical characteristics and availability of different therapy options per institution in each country.

NCT ID: NCT03955445 Recruiting - C3 Glomerulopathy Clinical Trials

Long-term Efficacy, Safety and Tolerability of LNP023 in C3G

Start date: October 3, 2019
Phase: Phase 3
Study type: Interventional

This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy

NCT ID: NCT03955146 Terminated - Clinical trials for Idiopathic Pulmonary Fibrosis

Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Start date: June 18, 2019
Phase: Phase 3
Study type: Interventional

This is a Phase 3 trial to evaluate the efficacy and safety of 30 milligrams (mg)/kilogram (kg) intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in participants with IPF.